Transitional cell (urothelial) carcinoma of the bladder is the second most common urologic
malignancy and is one of the best understood neoplasms, with relatively well-defined …

The unprecedented advances in cancer genetics and genomics are rapidly affecting the
clinical management of solid tumors. Molecular diagnostics are now an integral part of …

Bladder cancer occurs in the epithelial lining of the urinary bladder and is amongst the most
common types of cancer in humans, killing thousands of people a year. This paper is based …

Bladder cancer is the most common malignancy of the urinary tract and arising from the
epithelial lining of the urinary bladder. Resistance to cytotoxic therapies is associated with …

Human epidermal growth factor receptor 2 (HER2) is an important biomarker for breast and
gastric cancer prognosis and patient treatment decisions. HER2 positivity, as defined by IHC …

Human epidermal growth factor receptor-2 (HER2) is a well-recognized growth-promoting
factor in cancer, although its application to urothelial carcinoma has been limited because of …

We evaluated primary tumors from two cohorts, Spain (N= 111) and Greece (N= 102), for
patients who were treated with platinum‐based chemotherapy. Patients were tested for …

Micropapillary carcinoma of the bladder (MPBC) is a variant type of infiltrating urothelial
carcinoma, which portends a poor biological behavior in terms of disease stage at first …

Micropapillary urothelial carcinoma (MPUC) is a rare but an aggressive variant of urothelial
carcinoma. MPUC has been shown to commonly exhibit ERBB2 amplification and HER2 …

Bladder cancer is a common malignancy and a frequent cause of cancer-related death
worldwide. The benefit from current chemotherapy has reached a relative plateau, thus …